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Since 2000, the incidence of L. monocytogenes has
increased in Denmark (Fig. 2), as in several other European
countries [4]. Surveillance based on typing has not previously
suggested single-source outbreaks of listeriosis [7] and there
is presently no good explanation for the observed increase.
A review on 37 Danish foeto-maternal cases of listeriosis in
a 10-year period [8] did not ﬁnd evidence of epidemiological
relatedness.
The outbreak described here was suspected because local
diagnostic laboratories experienced unusual high numbers of
culture-conﬁrmed cases within a very short time span. Fast
and efﬁcient genotyping of the isolated bacteria was instru-
mental in distinguishing outbreak cases from sporadic cases.
Several cases notiﬁed in the same time period, including that
of a neonatal patient, could be excluded from the outbreak
on the basis of the genotyping.
The various aspects of listeriosis epidemiology have
recently been reviewed [9]. The long incubation period of
listeriosis, in the range 21–27 days for this outbreak, contrib-
utes to the difﬁculties in recognizing and investigating out-
breaks [1]. At the time the occurrence of an outbreak is
realized, valid information on food intake is almost impossi-
ble to obtain from the patients. Outbreaks of listeriosis may
be discovered because of their particular geographical loca-
tion, or because they mainly affect selected groups of individ-
uals, or with genotyping. [4].
Ready-to-eat products constitute a well known risk for
listeriosis outbreaks [10] and guidelines recommend that,
if the product is to be stored before consumption, the
number of L. monocytogenes bacteria should not exceed
100 cfu/g [1]. Precautions against L. monocytogenes are par-
ticularly important when ready-to-eat food is distributed to
vulnerable persons. Food may be handled differently from
what was intended in people’s homes and may be ingested
without prior heating or stored for prolonged periods of
time.
The outbreak described here incurred substantial health
costs and caused considerable public concern because recipi-
ents of meals-on-wheels constitute a large group of people
with impaired health who are especially susceptible to Listeria
infection. Procedures intended to reduce contamination with
Listeria were not followed for the batch of cooked beef and
resulted in invasive disease in mainly elderly and immuno-
compromised patient.
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Abstract
In 2008, an increase in the prevalence of carbapenem-resistant
Klebsiella pneumoniae was noted in a 286-bed tertiary case hospi-
tal in Colombia, where 84 patients (32 infected and 52 colo-
nized) had positive cultures. The identiﬁed index patient came
from Israel for a liver transplantation. High level carbapenem
resistance was observed. Polymyxin B and tigecycline were the
only two antibiotics that remained active. PCR-restriction
fragment length polymorphism analysis and sequencing revealed
blaKPC-3 in the major clone, which was indistinguishable from the
52 Clinical Microbiology and Infection, Volume 17 Number 1, January 2011 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 50–56
K. pneumoniae carbapenemase-3-producing clone described pre-
viously in Israel. This exempliﬁes the threat posed by the global
spread of K. pneumoniae carbapenemase-producing pathogens.
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Reports of carbapenemases have been increasing over the
last few years, particularly the plasmid-mediated enzyme
Klebsiella pneumoniae carbapenemase (KPC) [1]. Although
KPCs are mostly identiﬁed in K. pneumoniae, they have also
been reported in other Enterobacteriaceae and in Pseudo-
monas spp. [1,2]. KPC-type enzymes in K. pneumoniae strains
were ﬁrst reported in 2001 in North Carolina (KPC-1) [3],
and the ﬁrst case outside the USA occurred in France [4].
Subsequently, its occurrence has been reported in other
countries [5–8].
This worrisome spread across multiple continents and
species has been related to a successful mobile genetic
element. Naas et al. [9] identiﬁed a novel 10 kb Tn3-based
transposon, Tn4401, which is at the origin of blaKPC-like
gene acquisition and dissemination in both K. pneumoniae and
Pseudomonas aeruginosa from multiple countries. Molecular
epidemiology of KPC-producing K. pneumoniae isolates, using
multilocus sequence typing, has also revealed the successful
dissemination throughout the USA as well as in other coun-
tries (including Israel, India, Poland and Italy) of a single
sequence type 258 clone [10–12].
During 2008, an increase of carbapenem-resistant K. pneu-
moniae (CRKP, deﬁned as K. pneumoniae with imipenem or
meropenem MICs ‡ 16 mg/L) was observed in a Colombian
286-bed tertiary case hospital located in Medellin, where the
ﬁrst KPC-2 in Colombia was reported [5]. As a result, the
hospital infection control committee started an extensive
investigation to determine the source of the outbreak.
A patient from Israel admitted for a liver transplantation
was identiﬁed as the index case. He was admitted to the
hospital on 11 January 2008 and taken to surgery the next
day. Four days later, in the intensive care unit (ICU), he was
started on meropenem and linezolid as a result of suspected
nosocomial pneumonia. Bronchoalveolar lavage cultures grew
K. pneumoniae resistant to piperacillin/tazobactam, third and
fourth generation cephalosporins, ciproﬂoxacin, amikacin, im-
ipenem and meropenem. The isolate was only susceptible to
polymyxin B and tigecycline. He was started on both of these
on 21 January 2008 (unknown doses) but, 1 week later,
when still on treatment, new cultures from ascitic ﬂuid came
back positive for the same organism, and so rifampin was
added to the regimen for synergy. Despite the antibiotic reg-
imen used, cultures from respiratory secretions, ascitic ﬂuid
and urine remained positive. The patient was sent back to
Israel on 6 April 2008, when on treatment with polymyxin B,
rifampin and minocycline.
Infection control procedures were implemented when the
index case was detected: isolation, barrier precautions and
surveillance cultures from rectal and tracheal aspiration
grown on MacConkey agar supplemented with meropenem
(4 mg/L), were conducted for all hospitalized patients in the
ICU. By 31 December 2008, 84 patients had positive cultures
for CRKP, of whom 32 were considered infected and 52
colonized by CDC deﬁnitions [13]. Twenty out of the 32
infected patients died and 14 fulﬁlled the criteria of infection-
attributed mortality [14]. Sites of sample isolation of the
infected patients included: urine (n = 11), tracheal secretion
(n = 7), abdominal cavity (n = 7), bloodstream (n = 3), bone
(n = 2), soft-tissue abscess (n = 1) and conjunctiva (n = 1).
The increasing rate of CRKP in 2008 compared to 2007
was estimated at 700%; it increased from four CRKP isolates
among 206 initial isolates of K. pneumoniae in 2007 (1.9%
prevalence) to 32 CRKP isolates among 208 initial isolates of
K. pneumoniae in 2008 (15% prevalence). The number of
CRKP decreased, but not to zero, with infection control
measures.
A subset of 49 clinical isolates from the 84 patients with
positive cultures for CRKP was sent to the International
Centre for Medical Research and Training (CIDEIM) for fur-
ther characterization. At CIDEIM, isolate identiﬁcation was
performed using VITEK 2 (bioMe´rieux, Marcy l’Etoile,
France). Antimicrobial susceptibility was determined by a
broth microdilution method according to the guidelines of
the CLSI using Sensititre plates produced by Trek diagnostics
(Westlake, OH, USA) [15,16]. Enterobacteriaceae interpreta-
tive criteria for tigecycline MICs were deﬁned based on the
US Food and Drug Administration breakpoint criteria (sus-
ceptible, £ 2mg/L). In the case of polymyxin B, resistant
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FIG. 1. Dendrogram of pulsed-ﬁeld gel electrophoresis data (XbaI digests) showing the relatedness of Klebsiella pneumoniae isolates. 36 isolates
belonged to the type Q clone and ﬁve isolates belonged to the type B clone. All isolates were PCR positive for blaKPC.
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‡ 4 mg/L, which is the CLSI cut-off for Acinetobacter spp. was
used, as recommended previously [17].
Fingerprinting was performed using pulsed-ﬁeld gel elec-
trophoresis (PFGE) of chromosomal DNA with XbaI diges-
tion (Promega, Madison, WI, USA) as described by Matushek
et al. [18]. Of the 49 isolates, two major genetic clusters
were obtained: clone Q with 36 isolates and clone B with
ﬁve isolates, with 84% and 87% similarity by PFGE, respec-
tively. The remaining eight clinical isolates yielded different
proﬁles by PFGE (Fig. 1). The index case isolate, which
belonged to clone Q, was sent to Tel Aviv Sourasky Medical
Centre for PFGE analysis. The isolate was indistinguishable
from the KPC-3-producing clone described previously by
Navon-Venezia et al. [19] causing outbreaks in Israel. This
clone has been identiﬁed as belonging to ST-258 [12].
The 36 isolates from clone Q exhibited resistance to all
broad-spectrum cephalosporins, b-lactam/b-lactamase inhibi-
tor combinations (ampicillin–sulbactam and piperacillin–tazo-
bactam), aztreonam, ciproﬂoxacin and carbapenems tested.
Ertapenem, imipenem and meropenem resistance was
observed in a range of 16–128 mg/L. The only two antibiot-
ics that remained active were: polymyxin B with a range of
£0.5–2 mg/L (MIC50: 2 lg/mL and MIC90: 2 mg/L) and tige-
cycline with a range of £0.5–4 lg/mL (MIC50: £0.5 lg/mL
and MIC90: 1 mg/L).
Sequence analysis of blaKPC gene on isolate 298918 (index
case) belonging to clone Q and isolate 318857 belonging to
clone B, performed in Colorado State University, conﬁrmed
the presence of blaKPC-3 and blaKPC-2, respectively. This result,
together with PCR-restriction fragment length polymorphism
(results not shown), suggests the presence of blaKPC-3 in the
rest of clone Q and blaKPC-2 in the rest of the clone B isolates.
The present study is the ﬁrst report of an outbreak of
KPC-3 in Colombia and South America, as well as a demon-
strated international occurrence of a clone of multidrug-
resistant (MDR) blaKPC-3-harbouring K. pneumoniae (MDR is
deﬁned as resistance to ‡3 antimicrobial agents that are con-
sidered to be effective against the respective pathogen) [20].
Recently, an intercontinental spread of a hyperepidemic
clone of KPC-3-producing K. pneumoniae was also reported
between the USA and Israel [19]. Similarly, the ﬁrst KPC-3-
producing K. pneumoniae isolates in the UK were highly
genetically related to a KPC-3-producing K. pneumoniae-
strain from Israel [8], and the situation is no different in
Norway and Sweden, where the emergence of K. pneumoniae
isolates harboring blaKPC-2 and blaKPC-3 was associated with
multiple import events and probable local transmission [6].
These examples of international transmission of highly
resistant, Gram-negative pathogens are particularly notewor-
thy because KPC producing pathogens are very difﬁcult and, in
some cases, impossible to treat with currently available antimi-
crobial agents, and are associated with high case fatality ratios.
Given the lack of novel Gram-negative agents in the anti-
microbial pipeline, we are left with limited options for pre-
vention, such as strengthening infection control and
antibiotic stewardship.
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